The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

Blood. 2016 Jul 7;128(1):138-40. doi: 10.1182/blood-2016-05-712828. Epub 2016 May 31.

Authors

Darryl P Leong¹, François Caron², Christopher Hillis³, Annie Duan², Jeff S Healey¹, Graeme Fraser³, Deborah Siegal⁴

Affiliations

¹ The Population Health Research Institute, Department of Medicine, and.
² The Population Health Research Institute.
³ Department of Oncology, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
⁴ Department of Medicine, and.

PMID: 27247135
DOI: 10.1182/blood-2016-05-712828

No abstract available

Publication types

Letter
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Animals
Atrial Fibrillation / chemically induced*
Atrial Fibrillation / etiology
Humans
Incidence
Leukemia / drug therapy
Lymphoma / drug therapy
Piperidines
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use

Substances

Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine